Search

everythinglearnresearchcommunity

for

Search:↓

Mice lacking the PPARγ gene in their fat cells had almost no fat tissue, severe metabolic problems, and abnormal development of other fat-related tissues.

Japanese infants fed hydrolysate formula may have low biotin levels.

Photobiomodulation therapy may speed up hair regrowth after chemotherapy in the short term.

Steroid sex hormones activate matriptase in prostate cancer cells but not in breast cancer cells.

DHL-HisZnNa may help reduce hair loss from chemotherapy, but more research is needed.

Testosterone treatment can improve sexual function and bone density in women but may have adverse effects and requires more research on safety and guidelines.

Chemotherapy significantly lowers Inhibin A levels in breast cancer patients.

Hair loss due to scalp metastasis from breast cancer, known as Neoplastic Alopecia, has a better survival rate than other scalp metastases and requires a biopsy for diagnosis.

Breast cancer survivors often face body image and sexual health issues, needing ongoing support and open communication with healthcare providers.

Evaluate postmenopausal women with high androgen levels using medical history, physical exams, lab tests, and imaging to manage health risks.

The document concludes that sex hormones and related compounds have various effects on health, with both potential benefits and risks.

CK 5/6 expression in breast cancer is linked to negative hormone receptor status and higher tumor grade.

ROR-alpha may increase the growth of certain breast cancer cells by boosting aromatase, which could affect breast cancer prognosis.

Hair loss is a common but often unreported side effect of cancer treatments, especially for breast and prostate cancers.

Hair loss is a common side effect of hormone treatments for cancer.

Some antiandrogens may lower testosterone better than others, but it's unclear which is best for feminization in transgender women; more research is needed.

Cyproterone acetate treatment is safe and causes mild feminization, which increases with added estrogen.

Chemotherapy causes hair loss starting soon after treatment begins and recovers about 3 months after ending, while tamoxifen does not significantly affect hair growth.

Taking 5-alpha reductase inhibitors might be linked to breast cancer in men.

The document concludes that targeting the androgen receptor may be a promising breast cancer treatment, especially for certain types.

Estrogens help reduce skin aging, and SERMs might offer similar benefits without the risks of hormone therapy.

5-alpha reductase inhibitors slightly increase the risk of sexual and mood side effects, and breast growth in men.

The analysis shows the U.S. leads in tissue expansion research, mainly for breast reconstruction, with a slightly higher complication rate when using acellular dermal matrix.

Women have a higher risk of blood clots from hormonal factors and need careful treatment, especially during pregnancy.

Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.

The book is a detailed guide for plastic surgeons with clear explanations and is recommended for both new and experienced practitioners.

Cosmetic procedures can trigger pemphigus, an autoimmune disease.

Spironolactone does not increase the risk of breast cancer recurrence.

The document explains breast development, common breast conditions, and their treatments.

Hair analysis may help detect breast cancer early by identifying changes in lipid content.